<DOC>
	<DOCNO>NCT02807077</DOCNO>
	<brief_summary>This Phase 1 open label , single dose , 5 parallel-group study single 400 mg dose pacritinib administer orally patient renal impairment ( mild , moderate , severe , patient ESRD require hemodialysis ) sex- , age- weight-matched healthy subjects.Patients ESRD receive single 400 mg dose pacritinib 2 different treatment period : Dialysis Inter-Dialysis . The primary objective study evaluate pharmacokinetics safety pacritinib renal impairment .</brief_summary>
	<brief_title>To Determine PK Pacritinib Patients With Mild , Moderate , Severe Renal Impairment ESRD Compared Healthy Subjects</brief_title>
	<detailed_description>Groups 1 , 2 , 3 consist 8 patient mild , moderate , severe renal disease , respectively , base estimate glomerular filtration rate ( eGFR , calculated Modification Diet Renal Disease [ MDRD ] study equation ) . Each patient receive single 400 mg dose pacritinib . Group 4 consist 8 patient ESRD require hemodialysis stable dialysis regimen least 6 month . In cohort , patient participate 2 treatment period , Dialysis Inter-Dialysis , separate 14-day period pacritinib administration . In Dialysis Treatment Period , single 400 mg dose pacritinib administer 4 hour prior patient 's normally schedule hemodialysis . In Inter-Dialysis Treatment Period , single 400 mg dose pacritinib administer immediately end patient 's normally schedule hemodialysis session . Group 5 consist 8 healthy subject enrol match sex- , age- , weight patient mild , moderate , severe renal impairment patient ESRD enrol study . Healthy subject administer single 400 mg dose pacritinib .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>All Study Participants 1 . Male and/or female participant age 18 85 year ( inclusive ) 2 . Male , nonfertile female female childbearing potential use medically approve birth control method Females must nonpregnant nonlactating , females childbearing potential must postmenopausal least 1 year surgically sterile ( e.g. , tubal ligation , hysterectomy ) least 90 day , agree use contraception time sign informed consent 10 day prior Checkin ( Day 1 ) 30 day Study Completion . One follow form contraception must use time sign informed consent 10 day prior Checkin ( Day 1 ) 14 day final dose administration : nonhormonal intrauterine device ( IUD ) spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ( e.g. , NuvaRing® ) ; diaphragm spermicide ; cervical cap spermicide ; male sexual partner agree use male condom spermicide ; sterile sexual partner ; abstinence . Oral , implantable , transdermal , injectable contraceptive may use time sign informed consent 10 day prior Checkin ( Day 1 ) 14 day final dose administration . For female , pregnancy test result must negative Screening Checkin ( Day 1 ) Males sterile , completely abstain sexual intercourse , agree use , Checkin ( Day 1 ) 90 day follow Study Completion/ET , one follow approve method contraception : male condom spermicide ; sterile sexual partner ; use female sexual partner IUD spermicide ; female condom spermicide ; contraceptive sponge spermicide ; intravaginal system ; diaphragm spermicide ; cervical cap spermicide ; oral , implantable , transdermal , injectable contraceptive . Participants refrain sperm donation Checkin ( Day 1 ) 90 day follow Study Completion 3 . Body mass index ( BMI ) 1833kg/m2 ( inclusive ) Screening 4 . Negative test select drug abuse ( include alcohol ) Screening Checkin ( Day 1 ) Groups 13 5 . Negative test select drug abuse ( include alcohol ) require Screening Group 4 5 . Negative hepatitis panel ( include hepatitis B surface antigen [ HBsAg ] hepatitis C virus antibody [ anti HCV ] ) negative human immunodeficiency virus ( HIV ) antibody screen 6 . Able communicate well investigator , understand comply requirement study . Understand sign write informed consent . Legal authorize representative permit Patients Renal Impairment Only In addition inclusion criterion specify `` All Study Participants '' , patient renal impairment must meet following criterion : 7 . Have stable renal disease without evidence progressive renal disease ( i.e . know significant change eGFR 12 week ) mild renal impairment : eGFR 6089 mL/min/1.73 m2 moderate renal impairment : eGFR 3059 mL/min/1.73 m2 severe renal impairment : CrCl eGFR 1529 mL/min/1.73 m2 ESRD : require dialysis stable dialysis regimen least 6 month Renal function determine Screening serum creatinine value use MDRD Study equation 8 . Vital sign ( 5 minute rest measure supine position ) within follow range guidance Investigator : oral body temperature 35.037.8 °C systolic blood pressure , 95180 mm Hg diastolic blood pressure , 5595 mm Hg pulse rate , 5095 bpm Blood pressure pulse take stand position . After 3 minute stand , shall 20 mm Hg drop systolic 10 mm Hg drop diastolic blood pressure associate symptomatic postural hypotension Healthy Subjects Only In addition inclusion criterion specify `` All Study Participants '' , healthy subject must meet following criterion : 9 . No history clinical manifestation clinically significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal ( e.g. , celiac disease , peptic ulcer , gastro esophageal reflux , inflammatory bowel disease ) , metabolic , allergic , dermatological , neurological , psychiatric disorder ( determined Investigator ; appendectomy cholecystectomy consider clinically significant disease ) 10 . Normal renal function , eGFR ≥90 mL/min/1.73m2 ( determined Screening serum creatinine use MDRD Study equation ) 11 . Matched enrolled patient renal impairment age class 025 , 2650 , 5175 , 76100 percentile age distribution 12 . Matched enrolled patient renal impairment weight ( BMI ) class 025 , 2650 , 5175 , 76100 percentile BMI distribution 13 . Matched accord sex distribution enrol patient renal impairment 14 . Vital sign ( 5 minute rest measure supine position ) within follow range guidance Investigator : oral body temperature 35.037.5 °C systolic blood pressure , 90160 mm Hg diastolic blood pressure , 50100 mm Hg pulse rate , 4590 bpm Blood pressure pulse take stand position . After 3 minute stand , shall 20 mm Hg drop systolic 10 mm Hg drop diastolic blood pressure associate symptomatic postural hypotension All Study Participants Participants meeting follow criterion exclude entry continuation study unless sponsor approval obtain : 1 . Pregnant lactate female 2 . Renal transplant time 3 . Liver cirrhosis positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody test result 4 . History immunodeficiency disease , include positive HIV antibody test result 5 . Acute renal failure 6 . History chronic recurrent urinary tract infection active within past 30 day 7 . History pelvic irradiation within past 30 day 8 . Alcohol related hepatic disease 9 . History malignancy except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp 10 . Any follow within past 6 month : myocardial infarction ( MI ) ( Screening ECG reveals pattern consistent MI date event determine , subject enter study discretion Investigator and/or local medical monitor , sponsor 's permission ) coronary artery bypass surgery percutaneous coronary intervention unstable angina stroke 11 . Past medical history clinically significant ECG abnormality , presence abnormal ECG ( Investigator 's opinion clinically significant ) , QTcF &gt; 450 msec , concomitant condition increase risk QTc interval prolongation ( e.g. , heart failure , hypokalemia [ define serum potassium &lt; 3.0mEq/L persistent refractory correction ] , family history long QT interval syndrome ) 12 . History significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator 13 . Any medical surgical condition might significantly interfere gastrointestinal absorption , distribution , metabolism , excretion investigational drug . This include history significant disease gastrointestinal tract , pancreas , liver , kidney , and/or bloodforming organ . It include appendectomy , cholecystectomy , hernia repair , underlie renal disease abnormality occur direct result renal disease renal impairment patient abnormality occur direct result renal disease 14 . History drug alcohol abuse within last 6 month , evidence recent drug alcohol abuse indicate laboratory assay conduct screen baseline evaluation 15 . Heavy use tobacco nicotinecontaining product within 6 month prior Checkin ( Day 1 ) entire study , define urinary cotinine &gt; 150 ng/mL 16 . Consumption alcohol caffeinecontaining food beverages 72 hour prior screen entire study 17 . Consumption grapefruitcontaining food beverage potent cytochrome P450 ( CYP ) 3A4 inhibitor inducer 7 day prior Checkin ( Day 1 ) entire study 18 . Participation investigational study drug trial receipt investigational study drug occur within 5 halflives 30 day prior Checkin ( Day 1 ) , whichever longer , entire study 19 . Use oral , implantable , injectable , transdermal contraceptive within 10 day prior Checkin ( Day 1 ) time sign informed consent ( female ) 14 day final dose administration 20 . Use overthecounter , nonprescription medication , vitamin , mineral ( except prescribe physician ) , within 14 day prior Checkin ( Day 1 ) entire study 21 . Use phytotherapeutic/herbal/plantderived preparation within 14 day prior Checkin ( Day 1 ) entire study 22 . Use potent inducer CYP3A4 within 30 day Checkin ( Day 1 ) 23 . Use potent inhibitor CYP3A4 within 15 day Checkin ( Day 1 ) 24 . Poor peripheral venous access 25 . Donation loss 400 mL blood plasma within 8 week prior Checkin ( Day 1 ) entire study 26 . Receipt blood product within 2 month prior Checkin ( Day 1 ) 27 . Any diarrhea vomiting Screening period Checkin ( Day 1 ) 28 . Any acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study 29 . Any following concomitant medication within 30 day Checkin ( Day 1 ) ( unless cite otherwise ) : potassiumsparing diuretic e.g . spironolactone , triamterene , amiloride ( within 14 day Checkin ) class Ia , Ib Ic III antiarrhythmic probenecid medication contraindicate moderate severe renally impaired population drug know frequent toxicity major organ system within 3 month Screening ( i.e. , cytostatic drug ) 30 . Any following ( repeat confirm ) laboratory abnormality Screening Checkin : Clinically significant ( judged Investigator consultation Sponsor ) laboratory abnormality except elevate blood urea nitrogen ( BUN ) , elevate serum creatinine , hyperglycemia , and/or glycosuria Alanine aminotransferase ( ALT ) &gt; 1.5xULN Aspartate aminotransferase ( AST ) &gt; 1.5xULN Total bilirubin &gt; 1.3x ULN ( unless due Gilbert 's Syndrome ) Hemoglobin &lt; 8 g/dL Laboratory testing may repeat prior dosing ( rule possible laboratory error ) 31 . Planned surgery study period 32 . Subjects deem vulnerable way imprisonment , remand detention Patients Renal Impairment Only In addition exclusion criterion specify `` All Subjects '' , patient renal impairment meet follow criterion exclude entry study : 33 . Any condition would compromise patient ' safety study participation 34 . Participants Groups 13 : Difficulty void urinary tract obstruction Checkin undergoing method dialysis ( hemodialysis , peritoneal dialysis ) 35 . Screening physical exam ECG finding consider clinical significance Investigator , laboratory evaluation outside normal reference range exception value relate renal impairment 36 . Any significant acute chronic disease ( except renal impairment ) unstable interfere objective study 37 . Any change stable dose regimen , either overthecounter prescription , chronic medical condition ( e.g . diabetes , dyslipidemia , renal impairment ) within 4 week precede dose Healthy Subjects Only In addition exclusion criterion specify `` All Study Participants '' , healthy subject meet follow criterion exclude entry study : 38 . Any screening baseline physical exam , EKG , laboratory outside normal range deem clinically significant Investigator . Results deem clinically significant Investigator consultation Sponsor allowable . 39 . Use prescription medication and/or product within 14 day prior Checkin ( Day 1 ) entire study 40 . History renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy subject</keyword>
</DOC>